Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.51 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.40 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.36 |
| ▸ | GLS | O94925 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29668743 | 1.00 | LMNA (0.62) | LMNAGAAKDM4EALDH1A1P2RX7 | |
| SCHEMBL1990464 | 1.00 | LMNA (0.62) | LMNAGAAKDM4EALDH1A1P2RX7 | |
| SCHEMBL20238201 | 1.00 | LMNA (0.62) | LMNAGAAKDM4EALDH1A1P2RX7 | |
| SCHEMBL29668909 | 1.00 | LMNA (0.62) | LMNAGAAKDM4EALDH1A1P2RX7 | |
| SCHEMBL15006926 | 0.85 | LMNA (0.47) | LMNAGAAKDM4EALDH1A1P2RX7 | |
| SCHEMBL1265290 | 0.85 | LMNA (0.47) | LMNAGAAKDM4EALDH1A1P2RX7 | |
| SCHEMBL1265292 | 0.85 | LMNA (0.47) | LMNAGAAKDM4EALDH1A1P2RX7 | |
| SCHEMBL8060723 | 0.85 | LMNA (0.46) | LMNAGAAKDM4EALDH1A1P2RX7 | |
| SCHEMBL31278291 | 0.81 | LMNA (0.69) | LMNAGAAKDM4EALDH1A1P2RX7 | |
| SCHEMBL2980839 | 0.80 | LMNA (0.71) | LMNAGAAKDM4EALDH1A1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110325531-B | Benzenesulfonamides and their use as therapeutic agents | 泽农医药公司 | 2022-05-27 | — | — | CN | disclosed |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-11-16 | — | — | US | disclosed |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-11-16 | — | — | US | disclosed |
| US-20210171537-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2021-06-10 | — | — | US | disclosed |
| US-20210171537-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2021-06-10 | — | — | US | disclosed |
| EP-3551626-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2019-10-16 | — | — | EP | disclosed |
| US-20180162868-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2018-06-14 | — | — | US | disclosed |
| US-20180162868-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2018-06-14 | — | — | US | disclosed |
| WO-2018106284-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018106284-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2018-06-14 | — | — | WO | disclosed |
| US-20180162868-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2018-06-14 | — | — | US | disclosed |
| EP-2939669-A1 | 3-KETO-N-PROPARGYL-1-AMINOINDAN | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2015-11-04 | — | — | EP | disclosed |
| US-20150045445-A1 | 3-KETO-N-PROPARGYL-1-AMINOINDAN | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2015-02-12 | — | — | US | disclosed |
| EP-2515891-A1 | 3-KETO-N-PROPARGYL-1-AMINOINDAN | Teva Pharmaceutical Industries Ltd. (IL) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011087791-A1 | 3-KETO-N-PROPARGYL-1-AMINOINDAN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-07-21 | — | — | WO | disclosed |
| US-20110152381-A1 | 3-KETO-N-PROPARGYL-1-AMINOINDAN | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2011-06-23 | — | — | US | disclosed |
| US-20110034469-A1 | Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034469-A1 | Heterocyclic Compound | BIRC5, XIAP, BIRC2 | LMNA 2598/4885GAA 1721/4885KDM4E 2625/4885 |
| US-20150045445-A1 | 3-KETO-N-PROPARGYL-1-AMINOINDAN | PKD1, NAT1, AAAS | LMNA 1507/4885GAA 1955/4885KDM4E 564/4885 |
| US-20110152381-A1 | 3-KETO-N-PROPARGYL-1-AMINOINDAN | PKD1, NAT1, AAAS | LMNA 1507/4885GAA 1955/4885KDM4E 564/4885 |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | KCND2, SCN1A, CACNA1D | LMNA 1478/4885GAA 2829/4885KDM4E 1408/4885 |
| US-20210171537-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | LMNA 1080/4885GAA 1697/4885KDM4E 1329/4885 |
| US-20180162868-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | LMNA 1080/4885GAA 1697/4885KDM4E 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.